CN101264088A - Antibiotics composition with stable content and rapid solubility - Google Patents
Antibiotics composition with stable content and rapid solubility Download PDFInfo
- Publication number
- CN101264088A CN101264088A CNA2008100892253A CN200810089225A CN101264088A CN 101264088 A CN101264088 A CN 101264088A CN A2008100892253 A CNA2008100892253 A CN A2008100892253A CN 200810089225 A CN200810089225 A CN 200810089225A CN 101264088 A CN101264088 A CN 101264088A
- Authority
- CN
- China
- Prior art keywords
- sodium
- value
- cefoperazone
- acid
- cefoperazone sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims description 29
- 239000003242 anti bacterial agent Substances 0.000 title abstract description 5
- 229940088710 antibiotic agent Drugs 0.000 title abstract 4
- NCFTXMQPRQZFMZ-WERGMSTESA-M Cefoperazone sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C([O-])=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 NCFTXMQPRQZFMZ-WERGMSTESA-M 0.000 claims abstract description 72
- 229960002417 cefoperazone sodium Drugs 0.000 claims abstract description 72
- 238000002360 preparation method Methods 0.000 claims abstract description 24
- 239000003781 beta lactamase inhibitor Substances 0.000 claims abstract description 23
- 229940126813 beta-lactamase inhibitor Drugs 0.000 claims abstract description 23
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 claims abstract description 23
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 23
- 238000003756 stirring Methods 0.000 claims description 22
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 20
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 17
- 239000007864 aqueous solution Substances 0.000 claims description 14
- 230000003115 biocidal effect Effects 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 13
- 239000008215 water for injection Substances 0.000 claims description 13
- 239000002131 composite material Substances 0.000 claims description 12
- 230000006837 decompression Effects 0.000 claims description 12
- 238000004821 distillation Methods 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 12
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 9
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
- 229930195725 Mannitol Natural products 0.000 claims description 8
- 239000000594 mannitol Substances 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- 239000000600 sorbitol Substances 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- -1 alkali metal salt Chemical class 0.000 claims description 5
- 239000004475 Arginine Substances 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 claims description 4
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 3
- 229960000367 inositol Drugs 0.000 claims description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 3
- 229960005256 sulbactam Drugs 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims description 2
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 claims description 2
- 241000195493 Cryptophyta Species 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920001503 Glucan Polymers 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229920003091 Methocel™ Polymers 0.000 claims description 2
- 239000001888 Peptone Substances 0.000 claims description 2
- 108010080698 Peptones Proteins 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229960003324 clavulanic acid Drugs 0.000 claims description 2
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 claims description 2
- 235000012343 cottonseed oil Nutrition 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 235000013882 gravy Nutrition 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 235000019319 peptone Nutrition 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 235000020183 skimmed milk Nutrition 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 239000000413 hydrolysate Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 12
- 230000008901 benefit Effects 0.000 abstract description 3
- 238000004090 dissolution Methods 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 238000002425 crystallisation Methods 0.000 abstract description 2
- 230000008025 crystallization Effects 0.000 abstract description 2
- 238000001802 infusion Methods 0.000 abstract description 2
- 239000007857 degradation product Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 27
- 239000008194 pharmaceutical composition Substances 0.000 description 23
- 238000009472 formulation Methods 0.000 description 20
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 18
- 238000005352 clarification Methods 0.000 description 14
- KLCDQSGLLRINHY-UHFFFAOYSA-N 1-phenyldiazenylnaphthalen-2-amine Chemical compound NC1=CC=C2C=CC=CC2=C1N=NC1=CC=CC=C1 KLCDQSGLLRINHY-UHFFFAOYSA-N 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000003513 alkali Substances 0.000 description 10
- 239000002994 raw material Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 235000017550 sodium carbonate Nutrition 0.000 description 8
- 150000003951 lactams Chemical class 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 239000004471 Glycine Substances 0.000 description 6
- 229960004682 cefoperazone Drugs 0.000 description 6
- 229940093181 glucose injection Drugs 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 235000011121 sodium hydroxide Nutrition 0.000 description 6
- 239000006227 byproduct Substances 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 229940090044 injection Drugs 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000012856 packing Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- NKZMPZCWBSWAOX-IBTYICNHSA-M Sulbactam sodium Chemical compound [Na+].O=S1(=O)C(C)(C)[C@H](C([O-])=O)N2C(=O)C[C@H]21 NKZMPZCWBSWAOX-IBTYICNHSA-M 0.000 description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 4
- 239000006184 cosolvent Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229960000614 sulbactam sodium Drugs 0.000 description 4
- 229960003865 tazobactam Drugs 0.000 description 4
- 239000012535 impurity Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- NDIURPSCHWTXDC-UHFFFAOYSA-N 2-(4,5-dimethoxy-2-nitrophenyl)acetohydrazide Chemical compound COC1=CC(CC(=O)NN)=C([N+]([O-])=O)C=C1OC NDIURPSCHWTXDC-UHFFFAOYSA-N 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 229940038649 clavulanate potassium Drugs 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000011169 microbiological contamination Methods 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- ABVRVIZBZKUTMK-JSYANWSFSA-M potassium clavulanate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 ABVRVIZBZKUTMK-JSYANWSFSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000012976 tarts Nutrition 0.000 description 2
- 229960000373 tazobactam sodium Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 2
- ROHHYGMDHXYPJS-WCCKRBBISA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;sodium Chemical compound [Na].OC(=O)[C@@H](N)CCCNC(N)=N ROHHYGMDHXYPJS-WCCKRBBISA-N 0.000 description 1
- BZSXEZOLBIJVQK-UHFFFAOYSA-N 2-methylsulfonylbenzoic acid Chemical compound CS(=O)(=O)C1=CC=CC=C1C(O)=O BZSXEZOLBIJVQK-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010001526 Air embolism Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- PVGBHEUCHKGFQP-UHFFFAOYSA-N sodium;n-[5-amino-2-(4-aminophenyl)sulfonylphenyl]sulfonylacetamide Chemical compound [Na+].CC(=O)NS(=O)(=O)C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 PVGBHEUCHKGFQP-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an antibiotics combination with stable content and rapid dissolution and the preparation method, which comprises cefoperazone sodium, Beta- lactamase inhibitor and pH regulator with weight proportion of 1 to 100 : 1 : 0.001 to 1. When the antibiotics combination is dilutedly administrated with clinical conventional infusion according to certain proportion, wherein, the content of the cefoperazone sodium can be kept stable and the dissolution is rapid without crystallization and degradation product and without influence of temperature, thereby solving the problems of content lowering of cefoperazone sodium and low solubility when similar drugs are used clinically. The antibiotics combination has the advantages of simple preparation method and high efficiency and easy industrialization.
Description
Technical field
The present invention relates to a kind of antibiotic composite, more particularly, the present invention relates to a kind of stable content, dissolves antibiotic composite fast.Simultaneously, the invention still further relates to the preparation method of described antibiotic composite.
Background technology
Cefoperazone sodium (cefoperazone) and belong to third generation cephalosporin with the compound formulation of beta-lactamase inhibitor, has a broad antifungal spectrum, effect is strong, and the false monospore of Aerugo is had stronger antibacterial action, concentration height in bile.Clinical practice for many years shows that its clinical efficacy is obvious, and adverse reaction rate is low, and anti-enzyme, wide spectrum are cheap, thereby is subjected to the approval of vast hospitalized patients deeply and is widely used, and is third generation cephalosporin class antibiotic the most commonly used at present.But in the process of clinical practice, it is found that the compound formulation that contains cefoperazone sodium and beta-lactamase inhibitor is dissolved in the transfusion to find muddyly that through regular meeting the content of cefoperazone sodium descends, therefore normal under a cloud is quality problems and stop using.Especially in winter, the spring of the northern area of China, when temperature is starkly lower than 10 ℃, add in the transfusion, more the reversibility that cefoperazone sodium takes place through regular meeting is separated out and is produced insoluble or the muddy phenomenon of milky so that have a strong impact on clinical use.
The stability of the compound formulation of cefoperazone sodium and beta-lactamase inhibitor content in solution and pH value height are in close relations.The pH value of the compound formulation of cefoperazone sodium and beta-lactamase inhibitor is the most stable at 4.5～6.5 o'clock, and when solution pH value＜4.5, the reversibility that has a part cefoperazone sodium is separated out and is produced the outward appearance muddiness, and the cefoperazone sodium content descends rapidly in the solution, does not meet pharmacopeia regulation and affects the treatment.And when pH value＞6.5, very easily decompose, can destroy the lactam nucleus of cefoperazone sodium, the cefoperazone sodium content is descended and produce by-product, cause the generation of untoward reaction.
The compound formulation of cefoperazone sodium and beta-lactamase inhibitor must be dissolved in it in diluent and can use when clinical use, it is the most frequently used clinically at present that to make dissolved diluent be 5-10% glucose injection and 5% glucose saline, its pH value is about 3.8, with this infuse prepare the compound formulation of cefoperazone sodium and beta-lactamase inhibitor after, this moment, the pH value of transfusion was 4.0, pH value does not meet 4.5～6.5 the scope that makes the cefoperazone sodium content constant, cefoperazone sodium will reversibility be separated out and is produced insoluble or the muddy phenomenon of milky, the cefoperazone sodium content descends in the solution, affect the treatment, and in a single day the cefoperazone sodium crystal of separating out flows in patient's the body and will cause great malpractice.This brings very big inconvenience and dangerous to clinical application, and can delay patient's administration time, causes the nurse to resist emotion to using this medicine to produce, and influences clinical use.
Bibliographical information is arranged: when this problem appears in clinical use, add sodium bicarbonate solution,, can reach the liquid appearance clarification as cosolvent.But the problem that occurs is, one, because of not having checkout equipment and standardization metering outfit in the scene, and sodium bicarbonate solution does not have clear and definite regulation during with which kind of concentration, and the amount of adding sodium bicarbonate solution does not have quantitative control, so can't the accuracy controlling pH value; And for making the cefoperazone sodium stable content very accurate to the requirement of solution pH value, when solution pH value＜4.5, the reversibility that has a small amount of cefoperazone sodium is separated out and is produced the outward appearance muddiness, the cefoperazone sodium content descends in the solution, do not meet the pharmacopeia regulation, affect the treatment, but 5% sodium bicarbonate solution addition surpasses a few tenths of milliliter, then will make pH value＞6.5, and cefoperazone sodium very easily decomposes under this pH, destroy the lactam nucleus of cefoperazone sodium, made the cefoperazone sodium content descend and the generation by-product, caused the generation of untoward reaction.Two, hospital clinical section office do not have aseptic environments to come for on-the-spot preparation sodium bicarbonate sterile solution.Three, clinical nurse does not have operant skill pharmaceutically mostly.This scheme has brought very large trouble for the in good time preparation of medicine, has also increased the chance of drug contamination simultaneously, has great risk, and malpractice very easily takes place.
Application number is that 200610034315.3 Chinese patent literature discloses a kind of stable cefoperazone sulbactam medicine compound preparation, by cefoperazone acid is that raw material is formed with sulbactam acid and sodium bicarbonate, proposed to solve the not enough problem of cefoperazone acid dissolubility in solution, but there is following tangible weak point in this invention: 1, raw material does not meet pharmacopeia and ejection preparation requirement, cefoperazone acid contains a large amount of harmful impurity, can't reach the content of Chinese Pharmacopoeia standard code without purifying, requirement such as clarity and pH value, not directly as medicinal raw material, otherwise its contained impurity can produce huge injury to human body; Lack the scientific theory foundation when 2, prescription designs.Cefoperazone acid is water insoluble, can not be as the medicinal raw material of injection, must be water-soluble as the raw material of injection, and must make cefoperazone sodium.Cefoperazone acid and cefoperazone sodium are two kinds of different materials, though production cefoperazone sodium, obtain with alkali generation neutralization reaction by cefoperazone acid, but excuse spore piperazine keto acid molecular weight is bigger, from cephalo piperazine keto acid is the process of the medicinal cefoperazone sodium of feedstock production, cefoperazone acid and alkali compounds as the reaction rate of sodium hydrogen carbonate powder and unlike the acid-base neutralization reaction fast like that, be the course of reaction of a complexity, it is very big influenced by temperature, pH value.And the destroyed and by-product of new generation of the lactam nucleus of the cefoperazone sodium that impurity that brings in the acid of raw material cefoperazone and violent aborning chemical reaction cause also remains in the lump and does not remove in the medicine, can produce huge murder by poisoning to human body like this; 3, so there is obvious labile state on the contrary in prescription, can react between each prescription.Cefoperazone acid is unstable on the contrary under the alkali condition of sodium bicarbonate on the one hand, and pH value is too high, and cefoperazone sodium very easily decomposed in＞6.5 o'clock, can destroy the lactam nucleus of cefoperazone acid, produced by-product, caused the generation of untoward reaction; In addition, the heat stability of sodium hydrogen carbonate powder itself is very poor, can decompose.When mixing chemical reaction can take place between the raw material on the other hand.Because cefoperazone acid is tart, sodium bicarbonate is an alkalescence, can react after the mixing, produces heat and with CO
2Produce, medicine not only decomposes is rotten and because of there being gas to produce, pressure is excessive in the bottle, is storing, and transports and use meeting generation bottle explosion.Chemical reaction is taking place in one of the very difficult imagination, and character constantly changes, unsettled medicine can be used on the human body.4, sodium carbonate or the sodium bicarbonate as cosolvent is the weak acid strong alkali compound, when being dissolved in acid solution, can reacting and emit CO
2And clinical transfusion commonly used is as 5% Glucose Liquid, 10% glucose injection and the equal slant acidity of 5% glucose saline, thus with sodium carbonate or sodium bicarbonate as cosolvent, when dilution, can constantly produce CO in the process
2Gas may pollute medicinal liquid if bleeding is improper, CO in the infusion process
2Bubble enters in the blood samples of patients may form gas embolism, as obstruction appear at the heart, the main blood vessel of brain can cause very big danger to the patient.
The Chinese patent literature of application number 200610074928.X discloses a kind of preparation method of soluble compound medicinal preparation of antibacterial drugs, be with component A: acceptable pharmaceutical salts or hydrate on its physiology of furbenicillin, with B component: the salt of a kind of pharmaceutically acceptable water-soluble alkali or alkaline-earth metal, organic base, organic acid or salt one or more, make the solvent of aseptic dissolved constituent A, two bottles are placed in the packing box, are combined into the combination type injection.The pharmaceutical composition that will contain beta-lactamase inhibitor and cefoperazone sodium as the method with reference to this patent is made the A bottle, the salt of water-soluble alkali or alkaline-earth metal is made the B bottle, two bottles are placed in the packing box, be combined into the combination type injection, but still following deficiency is arranged: 1, stable at 4.5～6.5 o'clock because of the pH value of this pharmaceutical composition, narrow range, as long as the alkali of trace just can make the pH value of solution greater than 6.5, can destroy the lactam nucleus of cefoperazone acid, produce by-product, cause the generation of untoward reaction.Therefore consumption that must strict control alkali, and trace (several ten minutes several milligrams) like this are difficult to produce independent one bottle under present working condition.2, two bottles of combinations not only increase packing cost but also the clinical very trouble that uses, and the puncture back and forth of syringe needle has also increased the chance of medicine microbiological contamination.In the liquid feeding course of dissolution, cosolvent sodium carbonate or sodium bicarbonate commonly used can produce gas, and pressure of the inside of a bottle is increased when 3, making up a prescription.Because too high pressure of the inside of a bottle causes in taking out the medicine process easily the needle tubing piston to be ejected, or has liquid to overflow from breather in transfusion in early days, cause underdosage or drug contamination.
Therefore, when use contains the pharmaceutical composition of beta-lactamase inhibitor and cefoperazone sodium, to bring great convenience to clinical application if can solve the problem that contains beta-lactamase inhibitor and cefoperazone sodium pharmaceutical composition dissolubility, will alleviate nurse's workload greatly.If being arranged, method can guarantee the accurate adjusting to liquid pH value such as sodium bicarbonate, make it to be no more than pH value and be 6.5 and destroy the lactam nucleus of cefoperazone sodium, thereby keep the cefoperazone sodium stable content, the pharmaceutical composition that just more helps containing beta-lactamase inhibitor and cefoperazone sodium plays consistently its antibacterial action.But these perplex clinical use as the frequent de-stabilising effect clinical efficacy of cefoperazone sodium content, dissolubility is too low, the problem that pH value can't accurately be controlled under solid state is unresolved so far.
Summary of the invention
The object of the invention provides a kind of stable content and dissolves pharmaceutical composition fast, to solve the prior art above shortcomings.
Another purpose of the present invention provides a kind of preparation method of above-mentioned composition.
Stable content of the present invention and dissolve antibiotic composite fast, it is the preparation of being made by cefoperazone sodium, beta-lactamase inhibitor and pH value regulator, the weight proportion of each component is 1～100: 1: 0.001～1.
In above-mentioned composition, the weight proportion of each component is preferably 1～16: 1: 0.01～0.8
In above-mentioned composition, beta-lactamase inhibitor can be selected from one or more in the alkali metal salt of acid of clavulanic acid, sulbactam or his Batan acid.
In above-mentioned composition, the regulator of preferred pH value is selected from sodium hydrate aqueous solution, one or more in aqueous sodium carbonate, sodium bicarbonate aqueous solution and the arginine aqueous solution.
The prepared preparation of compositions of the present invention is preferably lyophilized preparation.
The preparation method of antibiotic composite of the present invention, comprise following steps: with cefoperazone sodium, beta-lactamase inhibitor and freeze drying protectant, add in the water for injection, stir and make it dissolving, control the pH value of solution 3～9 in titrating mode with the pH value regulator; Aseptic filtration, embedding through pre-freeze, decompression, distillation, drying, tamponade, is rolled lid in freeze dryer, and wherein pH value is preferably 4.5～6.5.
Preferred freeze drying protectant is selected from mannitol, glycine, lactose, gelatin hydrolysate, sorbitol, inositol, glucosan, sucrose, polyvinylpyrrolidone, glutamic acid, aspartic acid, Fructus Mali pumilae propylhomoserin, lactic acid, cottonseed sugar, trehalose, DL-threonine, xylitol, one or more in albumin, drum property albumen, peptone, arginine, histidine, soluble starch, dextrin, gravy, pectin, arabic gum, hydroxy methocel (CMC), algae, skim milk, serum, ascorbic acid, cysteine, azanol and the amido source.
It is raw material that the present invention adopts the stable cefoperazone sodium and the beta-lactamase inhibitor salt that meet the Chinese Pharmacopoeia standard, cefoperazone sodium and beta-lactamase inhibitor salt are fully dissolved, after uniformity ground distributes, finish with gas release in the pH value regulator adjust pH process, chemical reaction can not take place after the mixing in each component chemical stable in properties, and no gas produces, resulting good product quality, safety and good stability.
Specifically, in preparation method of the present invention, with cefoperazone sodium and beta-lactamase inhibitor with the water for injection dissolving after, use the pH value regulator, can accurately be transferred to 6.5 to pH value with accurate titrating method, reach the upper limit of cefoperazone sodium pH value (4.5～6.5) stability range, compound formulation with cefoperazone sodium and beta-lactamase inhibitor salt adds in tart 5-10% glucose injection and the transfusion of 5% glucose saline like this, the pH value of institute's obtain solution is 5.9, reach cefoperazone sodium pH value (4.5～6.5) stability range, the cefoperazone sodium stable content, the solution clarification.By to placing the solution of 24h, measure its pH value, reach pH value (4.5～6.5) stability range, measure stable content and do not reduce.
The present invention has adopted cefoperazone sodium and beta-lactamase inhibitor is fully dissolved, after reaching the distribution of uniformity ground, can accurately bring up to 6.5 to pH value with the pH value regulator with accurate titrating method, reach the upper limit of cefoperazone sodium pH value (4.5～6.5) stability range.Each component that the invention solves original invention is mixed inhomogeneous when pulverulence, and because of cefoperazone stable sodium pH value (4.5～6.5) narrow range, only need the alkali of trace to get final product, under solid state, can't accurately control and the difficult pH of adjustment, easily make pH value greater than 6.5, can destroy the lactam nucleus of cefoperazone acid.
In the present invention, adopt sodium hydroxide, sodium carbonate, sodium bicarbonate and arginine serve as the pH value regulator, and they are different with the raw material alkali that chemical reaction is served as in existing invention.As the pH regulator agent, solved that there is the easily excessive problem of the bad control of addition in sodium bicarbonate under the solid state with the aseptic aqueous solution of sodium hydroxide, sodium carbonate, sodium bicarbonate or arginic preferred 1% concentration.Make cefoperazone sodium stable p H-number scope (4.5～6.5) very narrow, each component is fully dissolved, uniformity ground distributes, and the concentration of pH value regulator must be very low, accurately the control pH value.
The present invention has adopted freeze dried preparation method, and cefoperazone sodium stable content, liquid pH value are regulated accurately the pharmaceutical composition aqueous solution under suitable condition, places it in lyophilizing in the freeze dryer, makes dried frozen aquatic products.This preparation method can make pharmaceutical composition of the present invention can make dried frozen aquatic products easily, easily for clinical use, brings into play huge economic benefit and social benefit.Adopt freeze dried preparation method of the present invention conveniently to regulate pH value, make stable liquid condition change into stable solid state.Mix under solid state with each component that original invention is adopted on minute assembling production lines, not only cause the uniformity may be bad and pH value can't accurately adjust and compare, the freeze dried preparation method of the present invention has major transformation, does not see document announcement and launch as yet.
The present invention only needs once with each components dissolved, after forming stable solution, fill lyophilizing in an antibiotic bottle, make product, with application number be that the Chinese patent literature disclosed " a kind of preparation method of soluble compound medicinal preparation of antibacterial drugs; make A bottle and B bottle; two bottles are placed in the packing box; be combined into the combination type injection " of 200610074928.X is compared, production cost and packing cost had both been reduced, avoided the chance of the medicine microbiological contamination that increases owing to puncturing back and forth of syringe needle again, convenient clinical use.
The specific embodiment
Following examples are used to illustrate the present invention, but are not used for limiting the scope of the invention.
Embodiment 1
With cefoperazone sodium 100g, sulbactam sodium 100g and mannitol 50g, add water for injection to 200ml, stir and make it dissolving, measure pH value, regulating pH value with the sodium hydrate aqueous solution of 1% concentration with titrating method is 6.5.Stirring makes fully evenly, aseptic filtration, and embedding, every bottle of 2ml in the freeze dryer lyophilizing, through pre-freeze, decompression, distillation, drying, tamponade, rolls lid, promptly gets 100 bottles of the lyophilized formulations of pharmaceutical composition of the present invention.
Embodiment 2
With cefoperazone sodium 100g, sodium-tazobactam 100g and mannitol 50g, add water for injection to 200ml, stir and make it dissolving, measure pH value, regulating pH value with the aqueous sodium carbonate of 1% concentration with titrating method is 6.4.Stirring makes dissolving, aseptic filtration, and embedding, every bottle of 2ml in the freeze dryer lyophilizing, through pre-freeze, decompression, distillation, drying, tamponade, rolls lid, promptly gets 100 bottles of the lyophilized formulations of pharmaceutical composition of the present invention.
Embodiment 3
With cefoperazone sodium 100g, sulbactam sodium 50g and sorbitol 30g, add water for injection to 200ml, stir and make it dissolving, measure pH value, regulating pH value with the sodium bicarbonate aqueous solution of 1% concentration with titrating method is 6.3.Stirring makes dissolving, aseptic filtration, and embedding, every bottle of 2ml in the freeze dryer lyophilizing, through pre-freeze, decompression, distillation, drying, tamponade, rolls lid, promptly gets 100 bottles of the lyophilized formulations of pharmaceutical composition of the present invention.
Embodiment 4
With cefoperazone sodium 100g, sodium-tazobactam 50g and sorbitol 30g, add water for injection to 200ml, stir and make it dissolving, measure pH value, be 6.2 with the aqueous solution of the sodium hydroxide of 1% concentration with titrating method adjusting pH value.Stirring makes dissolving, aseptic filtration, and embedding, every bottle of 2ml in the freeze dryer lyophilizing, through pre-freeze, decompression, distillation, drying, tamponade, rolls lid, promptly gets 100 bottles of the lyophilized formulations of pharmaceutical composition of the present invention.
Embodiment 5
With cefoperazone sodium 100g, sulbactam sodium 25g and glycine 30g, add water for injection to 200ml, stir and make it dissolving, measure pH value, be 6.0 with the aqueous solution of the sodium bicarbonate of 1% concentration with titrating method adjusting pH value.Stirring makes dissolving, aseptic filtration, and embedding, every bottle of 2ml in the freeze dryer lyophilizing, through pre-freeze, decompression, distillation, drying, tamponade, rolls lid, promptly gets 100 bottles of the lyophilized formulations of pharmaceutical composition of the present invention.
Embodiment 6
With cefoperazone sodium 100g, sodium-tazobactam 25g, glycine 30g and sorbitol 20g, add water for injection to 200ml, stir and make it dissolving, measure pH value, regulating pH value with the sodium hydrate aqueous solution of 1% concentration with titrating method is 5.9.Stirring makes dissolving, aseptic filtration, and embedding, every bottle of 2ml in the freeze dryer lyophilizing, through pre-freeze, decompression, distillation, drying, tamponade, rolls lid, promptly gets 100 bottles of the lyophilized formulations of pharmaceutical composition of the present invention.
Embodiment 7
With cefoperazone sodium 100g, sulbactam sodium 12.5g, mannitol 30g and sorbitol 30g, add water for injection to 200ml, stir and make it dissolving, measure pH value, be 5.8 with the smart sodium chlorate aqueous solution of 1% concentration with titrating method adjusting pH value.Stirring makes dissolving, aseptic filtration, and embedding, every bottle of 2ml in the freeze dryer lyophilizing, through pre-freeze, decompression, distillation, drying, tamponade, rolls lid, promptly gets 100 bottles of the lyophilized formulations of pharmaceutical composition of the present invention.
Embodiment 8
With cefoperazone sodium 100g, sodium-tazobactam 12.5g, mannitol 30g and glycine 30g, add water for injection to 200ml, stir and make it dissolving, measure pH value, regulating pH value with the aqueous sodium carbonate of 1% concentration with titrating method is 5.7.Stirring makes dissolving, aseptic filtration, and embedding, every bottle of 2ml in the freeze dryer lyophilizing, through pre-freeze, decompression, distillation, drying, tamponade, rolls lid, promptly gets 100 bottles of the lyophilized formulations of pharmaceutical composition of the present invention.
Embodiment 9
With cefoperazone sodium 100g, clavulanate potassium 100g, mannitol 30g and glycine 30g sorbitol 20g, add water for injection to 200ml, stir and make it dissolving, measure pH value, regulating pH value with the Arginine sodium aqueous solution of 1% concentration with titrating method is 6.5.Stirring makes dissolving, aseptic filtration, and embedding, every bottle of 2ml in the freeze dryer lyophilizing, through pre-freeze, decompression, distillation, drying, tamponade, rolls lid, promptly gets 100 bottles of the lyophilized formulations of pharmaceutical composition of the present invention.
Embodiment 10
With cefoperazone sodium 100g, clavulanate potassium 50g, sorbitol 20g, mannitol 30g, glycine 30g and inositol 10g, add water for injection to 200ml, stirring makes it dissolving, measures pH value, and regulating pH value with the sodium bicarbonate aqueous solution of 1% concentration with titrating method is 6.4.Stirring makes dissolving, aseptic filtration, and embedding, every bottle of 2ml in the freeze dryer lyophilizing, through pre-freeze, decompression, distillation, drying, tamponade, rolls lid, promptly gets 100 bottles of the lyophilized formulations of pharmaceutical composition of the present invention.
Experimental example 1
Pharmaceutical composition of the present invention is dissolved in 10% or 5% glucose injection, 5% Dextrose and Sodium Chloride Inj., behind the placement 24h, measures content, pH value and the dissolubility of cefoperazone sodium, result of the test is as shown in table 1:
Table 1
Table 1 result is as seen: pharmaceutical composition of the present invention is dissolved in 10% or 5% glucose injection, 5% Dextrose and Sodium Chloride Inj. of conventional slant acidity, place 24h after, it is constant and dissolubility good to survey stable content, the pH value of cefoperazone sodium.
Experimental example 2
With pharmaceutical composition lyophilized formulations of the present invention, placing under 40 ℃, relative humidity 75% condition the accelerated test result as shown in table 2:
Table 2
| Standard | 0 month | January | February | March | June | |
| PH value | 4.5-6.5 | 6.5 | 6.5 | 6.5 | 6.4 | 6.4 |
| The solution clarity | No. 1 turbidity standard | Clarification | Clarification | Clarification | Clarification | Clarification |
| Solution colour | Yellow No. 5 standard color solutions | Yellow No. 2 | Yellow No. 2 | Yellow No. 2 | Yellow No. 2 | Yellow No. 2 |
| The cefoperazone polymer | Answer 1.0 | 0.2％ | 0.2％ | 0.2％ | 0.2％ | 0.2％ |
| The cefoperazone sodium content | Labelled amount 90%-110% | 98％ | 98％ | 98％ | 97.9％ | 97.8％ |
| The Tazobactam Sodium sodium content | Labelled amount 90%-110% | 100.6％ | 100.6％ | 100.6％ | 100.5％ | 100.5％ |
Experimental example 3
With pharmaceutical composition lyophilized formulations of the present invention, place under 25 ℃, relative humidity 40% condition and do long-term stable experiment, the result is as shown in table 3:
Table 3
| Standard | 0 month | March | June | JIUYUE | December | 18 months | 24 months | |
| PH value | 4.5-6.5 | 6.5 | 6.5 | 6.5 | 6.5 | 6.5 | 6.4 | 6.4 |
| The solution clarity | No. 1 turbidity standard | Clarification | Clarification | Clarification | Clarification | Clarification | Clarification | Clarification |
| Solution colour | Yellow No. 5 standard color solutions | Yellow No. 2 | Yellow No. 2 | Yellow No. 2 | Yellow No. 2 | Yellow No. 2 | Yellow No. 2 | Yellow No. 2 |
| The cefoperazone polymer | Answer 1.0 | 0.2％ | 0.2％ | 0.2％ | 0.2％ | 0.2％ | 0.2％ | 0.2％ |
| The cefoperazone sodium content | Labelled amount 90%-110% | 98％ | 98％ | 98％ | 98％ | 98％ | 97.9％ | 97.9％ |
| The Tazobactam Sodium sodium content | Labelled amount 90%-110% | 100.6％ | 100.6％ | 100.6％ | 100.6％ | 100.5％ | 100.5％ | 100.5％ |
Table 2 and 3 results are as seen: pharmaceutical composition lyophilized formulations of the present invention in accelerated stability test and long-term stable experiment, constant product quality, the cefoperazone sodium stable content, pH value is constant, no cefoperazone sodium catabolite produces.
This shows, the invention solves former " in a single day cefoperazone sodium and beta-lactamase inhibitor add that the pH value of solution is 4.0 behind 5-10% glucose injection and 5% glucose saline; be lower than cefoperazone sodium pH value (4.5～6.5) stability range; thus cause cefoperazone sodium to separate out crystallization at solution, content descends " problem.
More than further illustrate content of the present invention by embodiment and experimental example, but should not be construed as limitation of the present invention.Those of ordinary skills will be understood that without departing from the spirit and substance of the case in the present invention component and the step of preparation method or modification or the replacement that condition is done to the present composition all fall among the scope of the present invention.
Claims (8)
1, a kind of antibiotic composite is characterized in that, is 1～100 by weight proportion: 1: 0.001～1 cefoperazone sodium, beta-lactamase inhibitor and pH value regulator are formed.
2, antibiotic composite according to claim 1 is characterized in that, weight proportion is 1～16: 1: 0.01～0.8.
3, antibiotic composite according to claim 1 and 2 is characterized in that, the pH regulator agent is sodium hydroxide, sodium carbonate, sodium bicarbonate and arginic aqueous solution.
According to each described antibiotic composite of claim 1-3, it is characterized in that 4, described beta-lactamase inhibitor is selected from one or more in the alkali metal salt of acid of clavulanic acid, sulbactam or his Batan acid.
According to each described antibiotic composite of claim 1-4, it is characterized in that 5, described compositions is a lyophilized preparation.
6, a kind of method for preparing the described antibiotic composite of claim 5, it comprises step: with cefoperazone sodium, beta-lactamase inhibitor, pH value regulator and freeze drying protectant, add in the water for injection, stir and make it dissolving, regulate pH value 3～9 with the pH value regulator; Aseptic filtration, embedding through pre-freeze, decompression, distillation, drying, tamponade, is rolled lid in freeze dryer, promptly get lyophilized preparation.
7, method according to claim 6 is characterized in that, regulates pH value 4.5～6.5.
8; according to claim 6 or 7 described methods; it is characterized in that; described freeze drying protectant is a mannitol; glycine; lactose; gelatin hydrolysate; sorbitol; inositol; glucosan; sucrose; polyvinylpyrrolidone; glutamic acid; aspartic acid; the Fructus Mali pumilae propylhomoserin; lactic acid; cottonseed sugar; trehalose; the DL-threonine; xylitol, albumin; drum property albumen; peptone; arginine; histidine; soluble starch; dextrin; gravy; pectin; arabic gum; hydroxy methocel; algae; skim milk; serum; ascorbic acid; cysteine; in azanol and the amido source one or more.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100892253A CN101264088B (en) | 2008-04-25 | 2008-04-25 | Antibiotics composition with stable content and rapid solubility |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100892253A CN101264088B (en) | 2008-04-25 | 2008-04-25 | Antibiotics composition with stable content and rapid solubility |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101264088A true CN101264088A (en) | 2008-09-17 |
| CN101264088B CN101264088B (en) | 2011-11-23 |
Family
ID=39986931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008100892253A Active CN101264088B (en) | 2008-04-25 | 2008-04-25 | Antibiotics composition with stable content and rapid solubility |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101264088B (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101912403A (en) * | 2010-08-02 | 2010-12-15 | 陶灵刚 | Cefoperazone sodium and tazobactam sodium medicinal composition microsphere injection |
| CN101914104A (en) * | 2010-08-20 | 2010-12-15 | 石家庄中硕药业集团有限公司 | Preparation method of lyophilization sulbactam sodium material medicine |
| CN102512374A (en) * | 2011-12-16 | 2012-06-27 | 苏州二叶制药有限公司 | Preparation process for cefoperazone sodium and tazobactam sodium for injection |
| CN103948602A (en) * | 2014-04-30 | 2014-07-30 | 成都苑东药业有限公司 | Cefoperazone sodium and tazobactam sodium medicinal composition for injection and preparation method thereof |
| CN105085543A (en) * | 2015-09-10 | 2015-11-25 | 青岛蓝盛洋医药生物科技有限责任公司 | Sulbactam sodium composition serving as antibacterial drug |
| CN107281480A (en) * | 2017-07-06 | 2017-10-24 | 商丘美兰生物工程有限公司 | A kind of heat-resisting lyophilized protecting agent of live vaccines of hog cholera |
| CN109432101A (en) * | 2018-12-03 | 2019-03-08 | 辽宁海思科制药有限公司 | Cefoperazone sodium and tazobactam sodium medicament composition and preparation method thereof |
| WO2019064065A1 (en) * | 2017-09-27 | 2019-04-04 | F. Hoffmann-La Roche Ag | Pharmaceutical forms of diazabicyclooctane derivatives and process for producing the same |
| US10584123B2 (en) | 2017-09-27 | 2020-03-10 | Fedora Pharmaceuticals Inc. | Pharmaceutical forms of diazabicyclooctane derivatives and manufacturing method thereof |
| CN110923145A (en) * | 2019-12-16 | 2020-03-27 | 天康生物股份有限公司 | Mycoplasma freeze-drying protective agent, freeze-dried mycoplasma and preparation method of freeze-dried mycoplasma |
| US10759800B2 (en) | 2017-09-27 | 2020-09-01 | Fedora Pharmaceuticals Inc. | Crystalline forms of diazabicyclooctane derivatives and production process thereof |
| CN114075560A (en) * | 2020-08-18 | 2022-02-22 | 杭州俊丰生物工程有限公司 | Stable composition of beta-lactamase |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1657046A (en) * | 2004-02-18 | 2005-08-24 | 苏大阳 | Powder injection composed of sodium cefoperazone and potassium clavulanate |
| CN1868478A (en) * | 2005-05-26 | 2006-11-29 | 广东诺康药业有限公司 | Compound prepn. injection contg. cefoperazone sodium and tazobactam sodium |
-
2008
- 2008-04-25 CN CN2008100892253A patent/CN101264088B/en active Active
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101912403A (en) * | 2010-08-02 | 2010-12-15 | 陶灵刚 | Cefoperazone sodium and tazobactam sodium medicinal composition microsphere injection |
| CN101912403B (en) * | 2010-08-02 | 2012-01-11 | 陶灵刚 | Cefoperazone sodium and tazobactam sodium medicinal composition microsphere injection |
| CN101914104A (en) * | 2010-08-20 | 2010-12-15 | 石家庄中硕药业集团有限公司 | Preparation method of lyophilization sulbactam sodium material medicine |
| CN102512374A (en) * | 2011-12-16 | 2012-06-27 | 苏州二叶制药有限公司 | Preparation process for cefoperazone sodium and tazobactam sodium for injection |
| CN103948602A (en) * | 2014-04-30 | 2014-07-30 | 成都苑东药业有限公司 | Cefoperazone sodium and tazobactam sodium medicinal composition for injection and preparation method thereof |
| CN103948602B (en) * | 2014-04-30 | 2015-05-06 | 成都苑东药业有限公司 | Cefoperazone sodium and tazobactam sodium medicinal composition for injection and preparation method thereof |
| CN105085543A (en) * | 2015-09-10 | 2015-11-25 | 青岛蓝盛洋医药生物科技有限责任公司 | Sulbactam sodium composition serving as antibacterial drug |
| CN107281480A (en) * | 2017-07-06 | 2017-10-24 | 商丘美兰生物工程有限公司 | A kind of heat-resisting lyophilized protecting agent of live vaccines of hog cholera |
| CN107281480B (en) * | 2017-07-06 | 2019-10-29 | 商丘美兰生物工程有限公司 | A kind of heat-resisting lyophilized protecting agent of live vaccines of hog cholera |
| US10682413B2 (en) | 2017-09-27 | 2020-06-16 | Fedora Pharmaceuticals Inc. | Pharmaceutical forms of diazabicyclooctane derivatives and process for producing the same |
| WO2019064065A1 (en) * | 2017-09-27 | 2019-04-04 | F. Hoffmann-La Roche Ag | Pharmaceutical forms of diazabicyclooctane derivatives and process for producing the same |
| US10584123B2 (en) | 2017-09-27 | 2020-03-10 | Fedora Pharmaceuticals Inc. | Pharmaceutical forms of diazabicyclooctane derivatives and manufacturing method thereof |
| US10759800B2 (en) | 2017-09-27 | 2020-09-01 | Fedora Pharmaceuticals Inc. | Crystalline forms of diazabicyclooctane derivatives and production process thereof |
| CN109432101A (en) * | 2018-12-03 | 2019-03-08 | 辽宁海思科制药有限公司 | Cefoperazone sodium and tazobactam sodium medicament composition and preparation method thereof |
| CN110923145A (en) * | 2019-12-16 | 2020-03-27 | 天康生物股份有限公司 | Mycoplasma freeze-drying protective agent, freeze-dried mycoplasma and preparation method of freeze-dried mycoplasma |
| CN110923145B (en) * | 2019-12-16 | 2021-07-20 | 天康制药(苏州)有限公司 | Mycoplasma freeze-drying protective agent, freeze-dried mycoplasma and preparation method of freeze-dried mycoplasma |
| CN114075560A (en) * | 2020-08-18 | 2022-02-22 | 杭州俊丰生物工程有限公司 | Stable composition of beta-lactamase |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101264088B (en) | 2011-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101264088B (en) | Antibiotics composition with stable content and rapid solubility | |
| CN101269072B (en) | Pharmaceutical composition containing beta-lactamase restrainer and piperacillin sodium with steady content and preparation method thereof | |
| CN102462684B (en) | Pharmaceutical composition of ceftriaxone sodium and sulbactam sodium and preparation method thereof | |
| CN101244043A (en) | Bivalirudin freeze-dried injection and preparation thereof | |
| CN101548679A (en) | Matrine type alkaloid microemulsion and preparation method thereof | |
| CN106137973A (en) | A kind of compound sulfonamide chloropyrazine soluble powder of sodium and preparation method thereof | |
| EP2113252A1 (en) | A forsythoside injection and preparation thereof | |
| CN101455631A (en) | Meglumine cyclic adenosine injection and preparation technique thereof | |
| CN105434351B (en) | A kind of compound fluocinonide spray and preparation method thereof | |
| CN104721155A (en) | Temozolomide lyophilized powder preparation and preparation method thereof | |
| CN102652744A (en) | Modified injection containing 13 compound vitamins and preparation method thereof | |
| CN101869302A (en) | Micro-emulsion calcium preparation and preparation method as well as application thereof | |
| CN112402371B (en) | Rudesiwei injection and preparation method thereof | |
| CN104997794A (en) | Long-acting composite vitamin oral emulsion for livestock and preparation method thereof | |
| CN101773507B (en) | Cefepime hydrochloride/arginine pharmaceutical composition suspension injection | |
| CN104434803A (en) | Artesunate and L-lysine composition for injection and preparation method therof | |
| CN102988305B (en) | Medicinal composition containing meglumine cyclic adenosine monophosphate compound | |
| CN103536603B (en) | A kind of wettability sulfamonomethoxine (sodium) powder and preparation method thereof | |
| FR2531860A1 (en) | IMPROVEMENTS TO VINCA ALKALOID COMPOSITIONS | |
| CN106074399B (en) | A kind of SC 69124 sodium freeze-dried preparation and preparation method thereof | |
| CN101569612A (en) | Lyophilized clindamycin phosphate powder needle reagent | |
| CN102988954B (en) | Medicinal composition containing thymopentin compound | |
| CN103417488A (en) | Adprin preparation for resisting coccidiosis and preparation method | |
| CN110849979A (en) | Detection method of zinc gluconate oral liquid | |
| RU2157698C1 (en) | Method of preparing preparation "pensulin cc" of insulin suspension for cartridge |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Hainan Tianhuang Pharmaceutical Co., Ltd. Assignor: Huang Zhifang Contract record no.: 2012460000006 Denomination of invention: Antibiotics composition with stable content and rapid solubility Granted publication date: 20111123 License type: Exclusive License Open date: 20080917 Record date: 20120524 |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200110 Address after: Room 901, building F6, No.9, Weidi Road, Xianlin street, Qixia District, Nanjing City, Jiangsu Province Patentee after: Nanjing fengkaisi pharmaceutical R & D Co., Ltd Address before: Jinan District of Fuzhou City, Fujian Province, Xiufeng road 350000 residential Theme Park Inc 55-105 Patentee before: Huang Zhifang |